BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33910002)

  • 1. Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma.
    Veo B; Danis E; Pierce A; Wang D; Fosmire S; Sullivan KD; Joshi M; Khanal S; Dahl N; Karam S; Serkova N; Venkataraman S; Vibhakar R
    Cell Rep; 2021 Apr; 35(4):109013. PubMed ID: 33910002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
    Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
    Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
    Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma.
    Kuzuoglu-Ozturk D; Aksoy O; Schmidt C; Lea R; Larson JD; Phelps RRL; Nasholm N; Holt M; Contreras A; Huang M; Wong-Michalak S; Shao H; Wechsler-Reya R; Phillips JJ; Gestwicki JE; Ruggero D; Weiss WA
    Cancer Res; 2023 Jan; 83(1):130-140. PubMed ID: 36264168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
    Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
    Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway.
    Crowther AJ; Ocasio JK; Fang F; Meidinger J; Wu J; Deal AM; Chang SX; Yuan H; Schmid R; Davis I; Gershon TR
    Cancer Res; 2016 Jun; 76(11):3211-23. PubMed ID: 27197166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
    BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
    Mo J; Liu F; Sun X; Huang H; Tan K; Zhao X; Li R; Jiang W; Sui Y; Chen X; Shen K; Zhang L; Ma J; Zhao K; Tang Y
    Cancer Res; 2021 Jun; 81(11):3105-3120. PubMed ID: 33853831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
    Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
    Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
    Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
    Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
    Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
    Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-myc overexpression causes anaplasia in medulloblastoma.
    Stearns D; Chaudhry A; Abel TW; Burger PC; Dang CV; Eberhart CG
    Cancer Res; 2006 Jan; 66(2):673-81. PubMed ID: 16423996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.